Ark Investment Management, the active investment firm led by Cathie Wood, increased positions in Figma, CoreWeave, and Recursion Pharmaceuticals during Friday trading, capitalizing on valuation declines across the three growth-oriented companies. The purchases reflect Wood's investment thesis around emerging technology trends, even as the stocks trade materially below their 2025 highs.
Figma, the design collaboration platform, demonstrated strong operational momentum with fourth-quarter revenue growth of 40% and margin expansion, providing fundamental support for the investment decision. CoreWeave, which provides GPU infrastructure services, continues to benefit from elevated demand driven by artificial intelligence development and deployment.
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, represents a longer-term technology bet despite recent headwinds. The company's valuation pressures intensified following Nvidia's exit from its equity stake, though the firm maintains its position as a computational biology player in early-stage clinical development.